M S Gordon

Summary

Affiliation: University of Arizona
Country: USA

Publications

  1. ncbi request reprint Phase I safety and pharmacokinetic study of recombinant human anti-vascular endothelial growth factor in patients with advanced cancer
    M S Gordon
    Indiana University School of Medicine, Indianapolis, IN, USA
    J Clin Oncol 19:843-50. 2001
  2. ncbi request reprint Managing patients treated with bevacizumab combination therapy
    Michael S Gordon
    Arizona Cancer Center, Greater Phoenix Area, Scottsdale, Ariz 85258, USA
    Oncology 69:25-33. 2005
  3. ncbi request reprint Novel antiangiogenic therapies for renal cell cancer
    Michael S Gordon
    Arizona Cancer Center Greater Phoenix Area, University of Arizona College of Medicine, Scottsdale, Arizona 85258, USA
    Clin Cancer Res 10:6377S-81S. 2004
  4. ncbi request reprint Managing anemia in the cancer patient: old problems, future solutions
    Michael S Gordon
    Arizona Health Sciences Center, University of Arizona, Phoenix, Arizona 85012, USA
    Oncologist 7:331-41. 2002
  5. pmc Overexpression of tumor vascular endothelial growth factor A may portend an increased likelihood of progression in a phase II trial of bevacizumab and erlotinib in resistant ovarian cancer
    Setsuko K Chambers
    Arizona Cancer Center, University of Arizona, Tucson, Arizona 85724 5024, USA
    Clin Cancer Res 16:5320-8. 2010
  6. doi request reprint A phase 2 clinical trial of nab-paclitaxel in previously treated and chemotherapy-naive patients with metastatic melanoma
    Evan M Hersh
    Department of Medicine, Arizona Cancer Center, Tucson, AZ 85724, USA
    Cancer 116:155-63. 2010
  7. ncbi request reprint Renal cell carcinoma: rationale and development of therapeutic inhibitors of angiogenesis
    Scot W Ebbinghaus
    Division of Hematology Oncology, University of Arizona College of Medicine, Arizona Cancer Center, 1515 North Campbell Avenue, Tucson, AZ 85724 5024, USA
    Hematol Oncol Clin North Am 18:1143-59, ix-x. 2004
  8. ncbi request reprint A phase I study of weekly gemcitabine and docetaxel in patients with advanced cancer: a Hoosier Oncology Group Study
    Kristen N Ganjoo
    Department of Medicine, Division of Hematology Oncology, Indiana University and The Walther Cancer Institute, Indianapolis, USA
    Oncology 62:299-304. 2002
  9. ncbi request reprint Clinical activity of pertuzumab (rhuMAb 2C4), a HER dimerization inhibitor, in advanced ovarian cancer: potential predictive relationship with tumor HER2 activation status
    Michael S Gordon
    Arizona Cancer Center, Tuscon and Scottsdale, AZ, USA
    J Clin Oncol 24:4324-32. 2006
  10. doi request reprint A phase 1 trial of 2 dose schedules of ABT-510, an antiangiogenic, thrombospondin-1-mimetic peptide, in patients with advanced cancer
    Michael S Gordon
    Premiere Oncology, Scottsdale, AZ, USA
    Cancer 113:3420-9. 2008

Detail Information

Publications26

  1. ncbi request reprint Phase I safety and pharmacokinetic study of recombinant human anti-vascular endothelial growth factor in patients with advanced cancer
    M S Gordon
    Indiana University School of Medicine, Indianapolis, IN, USA
    J Clin Oncol 19:843-50. 2001
    ..We investigated the safety and pharmacokinetics of a recombinant human monoclonal antibody to vascular endothelial growth factor (rhuMAb VEGF) in patients with cancer...
  2. ncbi request reprint Managing patients treated with bevacizumab combination therapy
    Michael S Gordon
    Arizona Cancer Center, Greater Phoenix Area, Scottsdale, Ariz 85258, USA
    Oncology 69:25-33. 2005
    ..The side-effect profile of bevacizumab makes it a suitable adjunct to standard chemotherapy in settings where efficacy has been demonstrated, and it is now approved for use in the USA, the European Union and other markets worldwide...
  3. ncbi request reprint Novel antiangiogenic therapies for renal cell cancer
    Michael S Gordon
    Arizona Cancer Center Greater Phoenix Area, University of Arizona College of Medicine, Scottsdale, Arizona 85258, USA
    Clin Cancer Res 10:6377S-81S. 2004
    ..Combinations of antiangiogenic agents either with other similarly acting drugs or as a component of a "cocktail" with other noncytotoxic therapies should be explored in this patient population...
  4. ncbi request reprint Managing anemia in the cancer patient: old problems, future solutions
    Michael S Gordon
    Arizona Health Sciences Center, University of Arizona, Phoenix, Arizona 85012, USA
    Oncologist 7:331-41. 2002
    ....
  5. pmc Overexpression of tumor vascular endothelial growth factor A may portend an increased likelihood of progression in a phase II trial of bevacizumab and erlotinib in resistant ovarian cancer
    Setsuko K Chambers
    Arizona Cancer Center, University of Arizona, Tucson, Arizona 85724 5024, USA
    Clin Cancer Res 16:5320-8. 2010
    ..This phase II trial evaluated bevacizumab plus erlotinib in platinum-resistant ovarian cancer; exploratory biomarker analyses, including that of tumor vascular endothelial growth factor A (VEGF-A), were also done...
  6. doi request reprint A phase 2 clinical trial of nab-paclitaxel in previously treated and chemotherapy-naive patients with metastatic melanoma
    Evan M Hersh
    Department of Medicine, Arizona Cancer Center, Tucson, AZ 85724, USA
    Cancer 116:155-63. 2010
    ..In the current study, the efficacy and safety of nab-paclitaxel were evaluated in previously treated and chemotherapy-naive patients with metastatic melanoma (MM)...
  7. ncbi request reprint Renal cell carcinoma: rationale and development of therapeutic inhibitors of angiogenesis
    Scot W Ebbinghaus
    Division of Hematology Oncology, University of Arizona College of Medicine, Arizona Cancer Center, 1515 North Campbell Avenue, Tucson, AZ 85724 5024, USA
    Hematol Oncol Clin North Am 18:1143-59, ix-x. 2004
    ....
  8. ncbi request reprint A phase I study of weekly gemcitabine and docetaxel in patients with advanced cancer: a Hoosier Oncology Group Study
    Kristen N Ganjoo
    Department of Medicine, Division of Hematology Oncology, Indiana University and The Walther Cancer Institute, Indianapolis, USA
    Oncology 62:299-304. 2002
    ..To determine the maximum tolerated dose (MTD) of weekly gemcitabine plus docetaxel, a dose escalation trial of both drugs was developed with each administered weekly for 3 weeks out of 4...
  9. ncbi request reprint Clinical activity of pertuzumab (rhuMAb 2C4), a HER dimerization inhibitor, in advanced ovarian cancer: potential predictive relationship with tumor HER2 activation status
    Michael S Gordon
    Arizona Cancer Center, Tuscon and Scottsdale, AZ, USA
    J Clin Oncol 24:4324-32. 2006
    ..Pertuzumab, a humanized antibody that prevents HER2 dimerization and inhibits multiple HER-mediated pathways, was studied in a phase II, multicenter trial in advanced, refractory OC...
  10. doi request reprint A phase 1 trial of 2 dose schedules of ABT-510, an antiangiogenic, thrombospondin-1-mimetic peptide, in patients with advanced cancer
    Michael S Gordon
    Premiere Oncology, Scottsdale, AZ, USA
    Cancer 113:3420-9. 2008
    ..The current study was designed to establish the safety of ABT-510 in the treatment of patients with advanced malignancies on a once-daily (QD) and twice-daily dosing schedule...
  11. doi request reprint Safety, pharmacokinetics, and pharmacodynamics of AMG 102, a fully human hepatocyte growth factor-neutralizing monoclonal antibody, in a first-in-human study of patients with advanced solid tumors
    Michael S Gordon
    Premiere Oncology of Arizona, Scottsdale, Arizona 85258, USA
    Clin Cancer Res 16:699-710. 2010
    ..The aims were to assess the safety, pharmacokinetics, maximum tolerated dose, and antitumor activity of AMG 102, a fully human hepatocyte growth factor/scatter factor (HGF/SF)-neutralizing monoclonal antibody, in patients with solid tumors...
  12. pmc Phase II study of erlotinib in patients with locally advanced or metastatic papillary histology renal cell cancer: SWOG S0317
    Michael S Gordon
    Premiere Oncology of Arizona, Scottsdale, AZ 85260, USA
    J Clin Oncol 27:5788-93. 2009
    ..In this trial, we evaluated the efficacy of erlotinib, an oral epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor in patients with advanced pRCC, a tumor type associated with wild-type von Hippel Lindau gene...
  13. doi request reprint Tumor angiogenesis and novel antiangiogenic strategies
    Michael S Gordon
    Premiere Oncology of Arizona, Scottsdale, AZ 85258, USA
    Int J Cancer 126:1777-87. 2010
    ..quot;Published 2008 Wiley-Liss, Inc. This article is a US Government work, and, as such, is in the public domain in the United States of America."..
  14. ncbi request reprint Phase II trial of subcutaneous recombinant human interleukin 11 with subcutaneous recombinant human granulocyte-macrophage colony stimulating factor in patients with acute myeloid leukemia (AML) receiving high-dose cytarabine during induction: ECOG 3997
    Larry D Cripe
    Indiana University Medical Center, Indianapolis, IN, United States
    Leuk Res 30:823-7. 2006
    ..I. 27-30 days) and 25 days (95% C.I. 24-29 days), respectively. The trial does not confirm the high CR rate observed in phase II trials, despite optimal supportive care...
  15. ncbi request reprint Alpha-v integrins as therapeutic targets in oncology
    Jeffrey A Nemeth
    Centocor, Inc, Radnor, Pennsylvania 19087, USA
    Cancer Invest 25:632-46. 2007
    ..This review focuses on the role of alpha(v) integrins in cancer progression, the current status of integrin-targeted agents in development, and strategies for the clinical development of anti-integrin therapies...
  16. ncbi request reprint Inhibitors of growth factor receptors, signaling pathways and angiogenesis as therapeutic molecular agents
    Jocelyn Holash
    Regeneron Pharmaceuticals, Tarrytown, NY, USA
    Cancer Metastasis Rev 25:243-52. 2006
  17. ncbi request reprint Overview of anti-VEGF therapy and angiogenesis. Part 1: Angiogenesis inhibition in solid tumor malignancies
    Lee M Ellis
    John Wayne Cancer Institute, Santa Monica, CA, USA
    Clin Adv Hematol Oncol 4:suppl 1-10; quz 11-2. 2006
    ..These other issues, including the biologic rationale for anti-VEGF therapy, as well as recent clinical trial data with anti-VEGF agents in colorectal, pancreatic, lung, kidney, and brease cancers, are discussed...
  18. ncbi request reprint Use of epoetin in patients with cancer: evidence-based clinical practice guidelines of the American Society of Clinical Oncology and the American Society of Hematology
    J Douglas Rizzo
    Medical College of Wisconsin, Milwaukee, WI 53226, USA
    Blood 100:2303-20. 2002
    ..Therefore, for anemic patients with hematologic malignancies it is recommended that physicians initiate conventional therapy and observe hematologic response before considering use of epoetin...
  19. ncbi request reprint Phase I clinical study of pertuzumab, a novel HER dimerization inhibitor, in patients with advanced cancer
    David B Agus
    Cedars Sinai Prostate Cancer Center and Medical Center, Los Angeles, CA 90048, USA
    J Clin Oncol 23:2534-43. 2005
    ..A clinical study was conducted to investigate safety and pharmacokinetics of pertuzumab and to perform a preliminary assessment of HER dimerization inhibition as a treatment strategy...
  20. ncbi request reprint Combination of trastuzumab and tanespimycin (17-AAG, KOS-953) is safe and active in trastuzumab-refractory HER-2 overexpressing breast cancer: a phase I dose-escalation study
    Shanu Modi
    Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
    J Clin Oncol 25:5410-7. 2007
    ..This phase I study examined whether a heat shock protein (Hsp) 90 inhibitor tanespimycin (17-AAG; KOS-953) could be administered safely in combination with trastuzumab at a dose that inhibits Hsp90 function in vivo in lymphocytes...
  21. ncbi request reprint Randomized phase III trial of high-dose interleukin-2 versus subcutaneous interleukin-2 and interferon in patients with metastatic renal cell carcinoma
    David F McDermott
    Department of Medicine, Division of Hematology Oncology, Beth Israel Deaconess Medical Center, 330 Brookline Ave, E KS 153, Boston, MA 02215, USA
    J Clin Oncol 23:133-41. 2005
    ..The Cytokine Working Group conducted a randomized phase III trial to determine the value of outpatient interleukin-2 (IL-2) and interferon alfa-2b (IFN) relative to high-dose (HD) IL-2 in patients with metastatic renal cell carcinoma...
  22. ncbi request reprint The emerging role of darbepoetin alfa in the management of patients with cancer
    Michael S Gordon
    J Support Oncol 2:2-3. 2004
  23. ncbi request reprint Innovations and challenges in renal cancer: consensus statement from the first international conference
    Michael B Atkins
    Beth Israel Deaconess Medical Center, Boston, Massachusetts 02215, USA
    Clin Cancer Res 10:6277S-81S. 2004
  24. ncbi request reprint Adjuvant high-dose bolus interleukin-2 for patients with high-risk renal cell carcinoma: a cytokine working group randomized trial
    Joseph I Clark
    Cardinal Bernardin Cancer Center, Loyola University Medical Center, 2160 South First Avenue, Maywood, IL 60153, USA
    J Clin Oncol 21:3133-40. 2003
    ..This prospective, randomized, controlled phase III trial assessed high-dose bolus interleukin-2 (IL-2) postoperatively in patients with high-risk renal cell carcinoma (RCC)...
  25. ncbi request reprint Use of epoetin in patients with cancer: evidence-based clinical practice guidelines of the American Society of Clinical Oncology and the American Society of Hematology
    J Douglas Rizzo
    Medical College of Wisconsin, Milwaukee, WI, USA
    J Clin Oncol 20:4083-107. 2002
    ..Therefore, for anemic patients with hematologic malignancies, it is recommended that physicians initiate conventional therapy and observe hematologic response before considering use of epoetin...
  26. ncbi request reprint Phase I trial of topotecan plus vinorelbine with/without filgrastim (G-CSF) in patients with refractory malignancies
    Nasser H Hanna
    Department of Medicine, Indiana University, Indianapolis, Indiana, U S A
    Am J Clin Oncol 25:337-9. 2002
    ..Subsequent combinations of these drugs, if warranted, should focus on alternate doses, schedules, or routes of administration...